Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | CD19 CAR-T for lymphoma: real-world experience in the UK

Andrea Kuhnl • 14 Jun 2020
EHA 2020
Lymphoma CAR-T
JULIET ZUMA-1

Andrea Kuhnl, MD, King’s College Hospital, London, United Kingdom, updates us on real-world experience in the UK of high-grade lymphoma patients treated with CD19 CAR T-cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrea Kuhnl

Widespread adoption of CAR-T therapy in the UK: fostering specialist networks
1:02
Widespread adoption of CAR-T therapy in the UK: fostering specialist networks
Andrea Kuhnl • 18 Jun 2025
The use of early PET responses to predict the risk of relapse after second-line axi-cel in LBCL
1:14
The use of early PET responses to predict the risk of relapse after second-line axi-cel in LBCL
Andrea Kuhnl • 18 Jun 2025
The efficacy and feasibility of using radiotherapy as a bridge to CAR-T in patients with lymphoma
1:27
The efficacy and feasibility of using radiotherapy as a bridge to CAR-T in patients with lymphoma
Andrea Kuhnl • 18 Jun 2025
Experience with the RESTART protocol: integrating radiotherapy into the peri-CAR-T setting for LBCL
1:33
Experience with the RESTART protocol: integrating radiotherapy into the peri-CAR-T setting for LBCL
Andrea Kuhnl • 18 Jun 2025

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals